Laura Panjwani

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Are the high costs of breakthrough therapies for blood cancers, some with price tags of more than $100,000 per year, worth the improved outcomes for patients?

The FDA has granted an orphan drug designation to Reolysin for the treatment of patients with ovarian cancer.

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

For insight on the evolving role of PARP inhibitors in the treatment of ovarian cancer, OncLive interviewed Donna McNamara, MD, co-chief of Gynecological Oncology at the John Theurer Cancer Center (JTCC).

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

Changing the administration schedule for gemcitabine plus nab-paclitaxel from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

Lanreotide (Somatuline Depot), which was recently approved by the FDA, is the first and only anti-tumor therapy with a statistically significant progression-free survival benefit in the treatment of adults patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs).